Although patient safety is a priority in oncology, few tools measure adverse events (AEs) beyond treatment-related toxicities. The study objective was to assemble a set of clinical triggers in the ...
AES Corporation's stock is a buy due to its solid dividend, portfolio optimization, and undervaluation based on DCF figures. The company is focusing on renewable energy sources and has a strong buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback